HELPER T CELL SUBPOPULATION ACTIVITIES IN HIV DISEASE

艾滋病毒疾病的一个主要并发症是呼吸道疾病恶化，这往往是过敏性的起源。 这是一项初步研究，以确定与HIV血清转换和疾病进展相关的IgE介导的呼吸道感染的患病率，并测试标准过敏原免疫治疗方案在这些HIV+患者中的安全性。4例患者入组研究，1例患者完成研究。 这些受试者有重度常年性过敏性鼻炎病史，对药物治疗反应差。 他们开始每周AIT，并监测CD 4群体，病毒载量和体外细胞因子产生。 结果显示，CD 4计数保持稳定，血浆病毒载量仍然检测不到。 体外破伤风诱导的IFNg水平增加，而IL-4和IL-10水平保持相对不变。 临床反应显著，症状评分下降，不再需要常规药物治疗。 这些数据表明，AIT可能在选定的HIV+患者中具有实用性，并支持需要进行更大规模的对照试验，以确定哪些HIV+患者可能会从这种治疗中受益。

A major complication of HIV disease is worsening respiratory conditions, which are often of allergic origin. This is a pilot study to identify prevalence of IgE-mediated respiratory correlated with HIV seroconversion and disease progression, and to test the safety of a standard allergen immunotherapy regimen in these HIV+ patients. Four patients have been enrolled in the study, and one has completed the study. These subjects have a history of severe perennial allergic rhinitis poorly responsive to medical therapy. They started weekly AIT and were monitored for CD4 populations, viral load and in vitro cytokine production. Results showed CD4 counts remained stable and plasma viral load remained undetectable. The in vitro tetanus-induced IFNg levels increased while IL-4 and IL-10 levels remained relatively unchanged. Clinical response has been remarkable, with symptom scores demising and need for regular medications no longer necessary. These data suggest that AIT may have utility in selected HIV+ patients and support the need for a larger controlled trial to establish which HIV+ patients might be expected to benefit from this therapy.